2017 Legislative Policy Update
|
|
|
- Horace Floyd
- 5 years ago
- Views:
Transcription
1 2017 Legislative Policy Update Aliyah N. Horton, CAE Executive Director Maryland Pharmacists Association
2 Presentation Overview Maryland Pharmacists Association General highlights of the session Pharmacy-related legislation Legislative and regulatory resources A few fun facts thrown in!
3 About MPhA VISION MPhA is the voice representing all Maryland pharmacists as innovative and respected members of the healthcare team focused on the health and well-being of Maryland residents. MISSION STRENGTHEN the profession of pharmacy ADVOCATE for all Maryland Pharmacists PROMOTE excellence in pharmacy practice
4 437 th Session Maryland General Assembly 90 days Nearly 3,000 bills & resolutions New HGO Leadership (Pendergrass & Bromwell)
5 Legislative Fun Fact Name the three committees in the General Assembly that have jurisdiction over pharmacy-related issues.
6 Bill Number (cross-file) SB0082 HB0584 Title Effective Comments Department of Health and Mental Hygiene Renaming Investigational Drugs, Biological Products and Devices Right to Try Act 07/01/17 Renaming DHMH to be the Maryland Department of Health and the head as the Secretary of Health 10/01/17 Authorizes a manufacturer of an investigational drug, biological products or device, to make eligible to patients; requires notification to patient and health care provider of side effects and risks; requires OAG to develop informed consent doc
7 Bill Number (cross-file) HB0602 (SB0422) Title Effective Comments Keep Antibiotics Effective Act of /01/17 Prohibits the administration of a antibiotics to drug to cattle, swine, or poultry solely for the purpose of promoting weight gain or improving feed efficiency. May be used to treat sick animals and to prevent disease outbreaks
8 Bill Number (cross-file) Legislation Title Effective Comments HB1273 Pharmacists Substitution and Dispensing of Biological Products 10/01/17 Authorizes a pharmacist to substitute an interchangeable biological product, of the same dosage form and strength, for any brand name drug under specified circumstances. Pharmacist notification will only be done once at the time of the initial substitution; can be done by several different means of communication.
9 Bill Number (cross-file) HB0613 (SB0363) Legislation Title Effective Comments Pharmacists - Contraceptives - Prescribing and Dispensing 07/01/17 Contraceptive medications and self-administered contraceptive devices; counseling services covered by public and commercial payers; pharmacist education waived for those who have received as part of their formal educational program; regulations must be promulgated by 09/18; pharmacists may begin to prescribing after 01/01/19.
10 Legislative Fun Fact What is the Maryland Pharmacy Coalition?
11 Bill Number (cross-file) HB1432 Title Effective Comments Health Care Providers Prescription Opioids Limits on Prescribing (The Prescriber Limits Act of 2017) 05/25/17 Requires health care providers to prescribe the lowest effective dose of an opioid and in a quantity no greater than needed for the duration; requires evidenced-based dosage, quantity and duration; authorizes disciplinary actions by health occupations board
12 Bill Number (cross-file) SB110 Title Effective Comments Public Health Expedited Partner Therapy Trichomoniasis and Pharmacist Dispensing 10/01/17 Authorizes a licensed pharmacist to dispense antibiotic therapy prescribed to any sexual partner of a patient diagnosed with chlamydia, gonorrhea or trichomoniasis under the State s expedited partner therapy (EPT) protocols.
13 Bill Number (cross-file) HB1147 (SB0898) Title Effective Comments Health Insurance Prescription Drugs Dispensing Synchronization 01/01/19 Payers to allow and apply a prorated daily copayment or coinsurance amount for a partial supply of a prescription drug dispensed by an in-network pharmacy; does not include Schedule II; allowed to override denial codes; pharmacists receive full dispensing fee
14 Legislative Fun Fact There is one pharmacist in the House of Delegates and one Congress. Do you know their names?
15 Bill Number (cross-file) SB0815 Title Effective Comments State Board of Pharmacy Registered Pharmacy Technicians Exemption for Pharmacy Students 10/01/17 Establishes an exemption from the requirement to register as a pharmacy technician for a pharmacy student who are currently completing the first year of a professional pharmacy education program.
16 Bill Number (cross-file) HB0631 Title Effective Comments Public Health Essential Off Patent or Generic Drugs Price Gouging - Prohibition 10/01/17 Legislation is limited to generic and off-patent drugs that experience unconscionable price increases. Attorney General authorized to take action if a manufacturer raises the cost of a drug to a level considered unjustifiable.
17 Bill Number (cross-file) HB1329 (SB0967) Title Effective Comments Heroin and Opioid Prevention Effort and Treatment Act of /25/17 Pharmacists may dispense naloxone to patients and caregivers, even if they don t have a certificate from the ORP programs. Expands ability of healthcare providers to write standing orders
18 Legislative Fun Fact How many members are their in the Maryland Congressional Delegation? Can you name them?
19 Withdrawn/Non-Passed Legislation PBM and Specialty Drugs- Related: MIA leading a summer study session Stakeholders (Insurers, PBMs, Pharmacy/ist groups, Managed Care and Hospital Systems) Issues: Specialty Drugs Any willing pharmacy/provider MAC enforcement/ retribution DIR-fees
20 Withdrawn/Non-Passed Legislation Pharmacist Practice Changes: Allow for flu vaccine from age 5 30 to 90 Day Conversion ( single dispensing) Issues: Delegates not comfortable with change in age No consensus between pharmacy stake holders and psychiatrists related to DAW
21 Withdrawn Legislation/Non-Passed Response to Opioid Epidemic: Required pharmacists to report to law enforcement if they provide treatment for a suspected overdose of a Schedule 1 Requirements to offer lockable vials for Schedules II-V Required notification of risks of opioid addiction Issues: Not an extension of law enforcement Not supporting unfunded mandates and legislated market share Unnecessary, already done as part of pharmacy SOP
22 Withdrawn/Non-Passed Legislation Other Health Occupations Authorized oncologists to dispense only to patients in same group practices Issues Bill allowed for a bypass of physician dispensing and pharmacy rules Authorized physician assistant dispensing Lack of experience and pharmacology education to engage in dispensing
23 Questions
24 Legislative and Regulatory Resources Maryland General Assembly Maryland Code of Regulations Fader s Pharmacy Law Book: Pharmacy Laws and Regulations for the State of Maryland/with updated supplement Resources
25 Thank you Maryland Pharmacists Association Facebook: /MarylandPharmacistsAssociation Website: Aliyah N. Horton, CAE Executive Director Phone:
MARYLAND BOARD OF PHARMACY
MARYLAND BOARD OF PHARMACY CONTRACEPTION REGULATIONSAnd Other Legislative Initiatives THE ROAD FROM CONCEPTUALIZATION TO IMPLEMENTATION Deena Speights-Napata Executive Director Maryland Board of Pharmacy
Public Health Impacts of 2016 West Virginia Legislation
Public Health Impacts of 2016 West Virginia Legislation Sherri A. Young, DO, FAAFP WVSOM Summer Seminar North Myrtle Beach, South Carolina June 15, 2016 1 Objectives Passage and implementation of Expedited
Michigan Legislative and Regulatory Pharmacy Initiatives Update
Michigan Legislative and Regulatory Pharmacy Initiatives Update Michigan Association of Health Plans Summer Conference Carrie Germain, R.Ph. Health Alliance Plan Senior Director, Pharmacy, Quality and
ISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy, Albuquerque, NM. [ NMAC - N, ; A, ]
![ISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy, Albuquerque, NM. [ NMAC - N, ; A, ]](/thumbs/92/109343672.jpg "ISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy, Albuquerque, NM. [ NMAC - N, ; A, ]")
TITLE 16 CHAPTER 19 PART 26 OCCUPATIONAL AND PROFESSIONAL LICENSING PHARMACISTS PHARMACIST PRESCRIPTIVE AUTHORITY 16.19.26.1 ISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy, Albuquerque,
September 1, The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201
September 1, 2017 The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Dear Secretary Price: The National Association of County
Sub. S.B. 119 As Passed by the Senate
AM3404 Sub. S.B. 119 As Passed by the Senate Topic: Opioid Data and Communication Expansion Act moved to amend as follows: In line 1 of the title, after "4723.52," insert "4729.01, 4729.44, 4729.75, 4729.79,
Ontario s Narcotics Strategy
Ontario s Narcotics Strategy Ontario Public Drug Programs Ministry of Health and Long-Term Care January 31, 2012 Ontario Harm Reduction Distribution Program Conference 2012 1 Background The Need for Action
DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT
c t DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this Act, current to September 22, 2014. It is intended
STATEMENT. of the. American Medical Association. for the Record. House Committee on Energy and Commerce
STATEMENT of the American Medical Association for the Record House Committee on Energy and Commerce RE: Federal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives October
Barriers, Concerns, and Recommended Course of Action for Expedited Partner Therapy for the Treatment of Gonorrhea and Chlamydia
Barriers, Concerns, and Recommended Course of Action for Expedited Partner Therapy for the Treatment of Gonorrhea and Chlamydia 15 March 2012 MALPH EPT 2 Introduction What is expedited partner therapy?
Dispensing and administration of emergency opioid antagonist without a
68-7-23. Dispensing and administration of emergency opioid antagonist without a prescription. (a) A pharmacist may dispense an FDA-approved emergency opioid antagonist and the necessary medical supplies
Prepublication Requirements
Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals
Pennsylvania Prescription Drug Monitoring Program Trends,
DEA Intelligence Report Brief DEA-PHL-DIR-006-17 Pennsylvania Prescription Drug Monitoring Program Trends, 2014-2015 December 2016 1 Executive Summary The abuse and diversion of pharmaceutical drugs, particularly
BOARD OF PHARMACY- REGULATORY UPDATE. Kimberly Grinston, J.D., Executive Director
BOARD OF PHARMACY- REGULATORY UPDATE Kimberly Grinston, J.D., Executive Director Disclosure and Conflict of Interest I declare no conflicts of interest, real or apparent, and no financial interest in any
Lobbyist-in-a-Box: (VPhAT) created on 01/15 at 10:11
Lobbyist-in-a-Box: (VPhAT) created on 01/15 at 10:11 HB 132 Controlled substances containing opioids; limits on prescription. Chief patron: Bell, John J. Limits on prescription of controlled substances
Performance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)
Performance of North Carolina's System for Monitoring Prescription Drug Abuse Session Law 2015-241, Section 12F.16.(q) Report to the Joint Legislative Oversight Committee on Health and Human Services and
PLEASE NOTE. For more information concerning the history of this Act, please see the Table of Public Acts.
PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this Act, current to July 1, 2012. It is intended for information and reference purposes only. This
Pennsylvania s Opioid Crisis: Data and Strategies to Combat It
Data and Strategies to Combat It May 8, 2018 Phillip M. Burrell Director, Research & Data Analytics The Hospital + Healthsystem Association of Pennsylvania Agenda The PA opioid crisis Trends Responses
2016 Jurisprudence Update. (Phone) (Fax)
2016 Jurisprudence Update (Phone) 614-466-4143 (Fax) 614-752-4836 www.pharmacy.ohio.gov Goals and Objectives To explain recent law/rule changes which may apply to the pharmacy practice setting. To describe
Louisiana. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Louisiana Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
A Bill Regular Session, 2015 SENATE BILL 717
Stricken language would be deleted from and underlined language would be added to present law. 0 State of Arkansas 0th General Assembly As Engrossed: S// H// A Bill Regular Session, SENATE BILL By: Senator
The Changing Landscape of Opioids & Workers Compensation. Presented by: David Campbell, MA, CRC State of Michigan Workers Compensation Agency
The Changing Landscape of Opioids & Workers Compensation Presented by: David Campbell, MA, CRC State of Michigan Workers Compensation Agency 1 The Changing Landscape of Opioids & Workers Compensation is
PREVENTING PRESCRIPTION DRUG ABUSE AND OVERDOSE JUNE 23, 2016 SHERRY L. GREEN
PREVENTING PRESCRIPTION DRUG ABUSE AND OVERDOSE JUNE 23, 2016 SHERRY L. GREEN STATE LAW AND POLICY TRENDS STATE PRESCRIPTION DRUG MONITORING PROGRAMS (PMPS) Transformation into better health care tools
Our Journey to Addressing the PA PDMP Program. Dean Parry, RPh AVP Clinical Informatics, Care Support Services Geisinger Health System
Our Journey to Addressing the PA PDMP Program Dean Parry, RPh AVP Clinical Informatics, Care Support Services Geisinger Health System 1 Geisinger Health System Geisinger Health System is an integrated
Guide to Interchangeable Medicines
Guide to Interchangeable Medicines AUT-G0115-6 01 JUNE 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS 1 BACKGROUND 3 1.1
Addressing the Opioid Epidemic in Tennessee
Addressing the Opioid Epidemic in Tennessee A Multidisciplinary Approach Melissa McPheeters, PhD, MPH Director, Informatics and Public Health Analytics 26 108 733 *Source: CDC References Centers for
Coventry Health Care of Georgia, Inc.
Coventry Health Care of Georgia, Inc. PRESCRIPTION DRUG RIDER (for High Deductible Health Plans) This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health Plan
Innovative Ways to Fund Harm Reduction Services New Mexico
Innovative Ways to Fund Harm Reduction Services New Mexico Laine M. Snow, MSW HIV Service Program Manager New Mexico Department of Health History and Importance of Harm Reduction New Mexico Sero-prevalence
ACCG Mental Health Summit
ACCG Mental Health Summit Sheila Pierce, Opioid Program Coordinator Director, Prescription Drug Management Program Discussion 1. Overview Opioid Problem in GA - Video 2. DPH Opioid Program 3. Priorities
Reducing Opioid Deaths: Arizona s Emergency Declaration & Response
Reducing Opioid Deaths: Arizona s Emergency Declaration & Response September 15, 2017 Sheila Sjolander, Assistant Director Arizona Department of Health Services Emergency Declaration On June 5, 2017, Arizona
VIRGINIA S OPIOID & HEROIN OVERDOSE EPIDEMIC
1 VIRGINIA S OPIOID & HEROIN OVERDOSE EPIDEMIC Virginia Association of Counties November 14, 2016 The Honorable William A. Hazel, Jr., M.D. Secretary of Health and Human Resources 1999 - Estimated drug
Fundamentals of Pharmacology for Veterinary Technicians Chapter 1
1906 1914 1933 1937 1938 1941 1951 1965 1968 1970 1970 1972 1972 1983 1984 1988 1994 1994 1996 1997 2001 2003 2008 The original Pure Food and Drug Act is passed by Congress on June 30 and signed by President
FlexRx 6-Tier. SM Pharmacy Benefit Guide
FlexRx 6-Tier SM Pharmacy Benefit Guide Welcome to FlexRx The AllWays Health Partners FlexRx SM program is built for choice, savings, and convenience with benefits including: Low-cost drug tier for many
Appendix F Federation of State Medical Boards
Appendix F Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office SECTION I: PREAMBLE The (name of board) recognizes that the prevalence of addiction
Confronting the Opioid Epidemic
Confronting the Opioid Epidemic Appropriately Treating Pain while Stopping Abuse Scott Kennedy, MD, Chief Medical Officer, Olympic Medical Center Ian Corbridge, RN, Clinical Policy Director, WSHA June
HOPE Agenda. Heroin, Opioid Prevention & Education WISCONSIN STATE REPRESENTATIVE JOHN NYGREN ASSEMBLY DISTRICT 89
HOPE Agenda Heroin, Opioid Prevention & Education WISCONSIN STATE REPRESENTATIVE JOHN NYGREN ASSEMBLY DISTRICT 89 In compliance with CMA regulation, I attest that I have no conflicts of interest associated
New Initiatives to Expand Access to Medication Assisted Treatment in NYS OASAS
New Initiatives to Expand Access to Medication Assisted Treatment in NYS OASAS Charles W. Morgan, MD, DFASAM, FAAFP Medical Director New York State Office of Alcoholism and Substance Abuse Services February
Opioid Treatment Program Reimbursement Re-bundling Proposal
Opioid Treatment Program Reimbursement Re-bundling Proposal Maryland Department of Health and Mental Hygiene April 22, 2016 The Department reviewed close to 50 letters and emails submitted by stakeholders
4/26/2018. Bureau of Professional Licensing. MAPS Updates & Opportunities. MAPS Background. Registration. MAPS Update
Bureau of Professional Licensing MAPS Updates & Opportunities April 28, 2018 Presented by Andrew Hudson, Manager Haley Winans, Analyst Drug Monitoring Section Bureau of Professional Licensing BPL-MAPS@Michigan.gov
The Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division
The Oregon Opioid Initiative State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division Disclosure No disclosures 2 Learning Objectives Learner will be able
Review of Controlled Drugs and Substances Act
Review of Controlled Drugs and Substances Act Canadian Medical Association: Submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations A
Schedules of Controlled Substances: Placement of Furanyl fentanyl, 4- Fluoroisobutyryl fentanyl, Acryl fentanyl, Tetrahydrofuranyl fentanyl, and
This document is scheduled to be published in the Federal Register on 11/29/2018 and available online at https://federalregister.gov/d/2018-26045, and on govinfo.gov Billing Code 4410-09-P DEPARTMENT OF
SENATE FILE NO. SF0042. Sponsored by: Joint Judiciary Interim Committee A BILL. for. AN ACT relating to public health and safety; creating the
0 STATE OF WYOMING LSO-000 SENATE FILE NO. SF00 Opiate overdose emergency treatment. Sponsored by: Joint Judiciary Interim Committee A BILL for AN ACT relating to public health and safety; creating the
A Bill Regular Session, 2015 SENATE BILL 880
Stricken language would be deleted from and underlined language would be added to present law. Act of the Regular Session 0 State of Arkansas 0th General Assembly As Engrossed: S// H// A Bill Regular Session,
The Opioid Epidemic: The State of the State
JOINT LEGISLATIVE COMMITTEE ON HEALTH AND HUMAN SERVICES The Opioid Epidemic: The State of the State Dr. Mandy Cohen, Dr. Susan Kansagra Department of Health and Human Services Nov. 14, 2017 3 PEOPLE DIE
COLORADO PRESCRIPTION DRUG MONITORING PROGRAM
COLORADO PRESCRIPTION DRUG MONITORING PROGRAM Harold Rogers Prescription Drug Monitoring Program West Regional Meeting Salt Lake City, Utah August 12 13, 2014 Tia Stakely, M.S. PDMP Administrator 2005
Guidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry DRAFT GUIDANCE This guidance
Legislative & Regulatory Update Brad Young, RxPlus Government Affairs
Legislative & Regulatory Update 2018 Brad Young, RxPlus Government Affairs Disclosures Brad Young reports no actual or potential conflicts of interest associated with this presentation. 2 Learning Objectives
Legislative and Regulatory Update Michael Baxter APhA Director, Regulatory Affairs
Legislative and Regulatory Update 2018 Michael Baxter APhA Director, Regulatory Affairs 1 CPE Information and Disclosures Michael Baxter declares no conflicts of interest, real or apparent, and no financial
Act 443 of 2009 House Bill 1379
Act 443 of 2009 House Bill 1379 AN ACT TO PROVIDE FOR THE LICENSURE OF ALCOHOLISM AND DRUG ABUSE COUNSELORS; TO PROVIDE FOR THE REGISTRATION OF CLINICAL ALCOHOLISM AND DRUG ABUSE COUNSELOR SUPERVISORS;
STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A.
STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A. Arizona Corporate Counsel Presentation May 8, 2018 Agenda 1. Overview of the Opioid
North Dakota Board of Pharmacy
North Dakota Board of Pharmacy Updates on Drug Abuse Trends, the PDMP and Medical Marijuana Mark J. Hardy, Pharm D Executive Director Disclosure Statement I have no conflict of interests to report Objectives
Employment Background Complete the application information Complete the application information
CERTIFICATION REQUIREMENTS SPECIALTY CERTIFICATION OVERVIEW This is not the Specialty Certification application. Application Initial Renewal Academic Background Complete the application information Complete
Opioid Guardianship Project: Combating the Opioid Crisis Sarah Derr, PharmD Meg Nugent, MHA, RN Iowa Healthcare Collaborative
Opioid Guardianship Project: Combating the Opioid Crisis Sarah Derr, PharmD Meg Nugent, MHA, RN Iowa Healthcare Collaborative Objectives Summarize the current crisis at the national and Iowa state level.
Michigan Opioid Legislation Hospital Compliance Checklist
MHA KEYSTONE CENTER MICHIGAN OPIOID LEGISLATION HOSPITAL COMPLIANCE CHECKLIST The Michigan Opioid Legislation was created by the Michigan Health & Hospital Association to help guide its member hospitals
IN-NETWORK MEMBER PAYS. Contract Year Plan Deductible (Deductible is combined for health services and prescription drugs) $5,000 Individual
HMO-OA-CNT-HSA-5000I/10000F-07 Contract Year Benefit Summary (E) Point-Of-Service Open Access High Deductible Health Plan (HDHP) for use with a Health Savings Account (HSA) This is a brief summary of benefits.
Pharmacy benefit guide
FlexRx SM 5-Tier Pharmacy benefit guide 1 Welcome to FlexRx The NHP FlexRx SM program is built for choice, savings, and convenience with benefits including: Low-cost drug tier for many common medications
Overdose Fatality Review
Overdose Fatality Review Erin Haas and Laura Bartolomei-Hill Department of Health and Mental Hygiene BJA Grantee meeting 3/30/2017 Overdose in Maryland What is Overdose Fatality Review? Modeled after
Vaccine Starter Kit Program FAQs
Vaccine Starter Kit Program FAQs Program How does this program help Health Mart pharmacies provide vaccines for their customers? McKesson has designed a comprehensive program specifically for Health Mart
Potential Solutions to Epidemic Substance Abuse in US and Europe
Potential Solutions to Epidemic Substance Abuse in US and Europe Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center, Denver Health 1 Professor, University of Colorado School of Medicine
2017 PGIP Fact Sheet Electronic Prescribing of Controlled Substances (EPCS)
2017 PGIP Fact Sheet Electronic Prescribing of Controlled Substances (EPCS) Overview Value Partnerships, in conjunction with the Blue Cross Pharmacy team, has created the Electronic Prescribing of Controlled
ASSEMBLY, No. 542 STATE OF NEW JERSEY. 218th LEGISLATURE PRE-FILED FOR INTRODUCTION IN THE 2018 SESSION
ASSEMBLY, No. STATE OF NEW JERSEY th LEGISLATURE PRE-FILED FOR INTRODUCTION IN THE 0 SESSION Sponsored by: Assemblyman VINCENT MAZZEO District (Atlantic) Assemblyman JOSEPH A. LAGANA District (Bergen and
The Opioid Addiction Crisis in the Northern Shenandoah Valley. A Community Response
The Opioid Addiction Crisis in the Northern Shenandoah Valley A Community Response 1 Overview of the Problem Objectives Formation of the Northern Shenandoah Valley Substance Abuse Coalition Roles of key
Minnesota. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Minnesota Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
On December 27, 2017, the Lieutenant Governor signed into law several new requirements
OPIOID Alert MICHIGAN OSTEOPATHIC ASSOCIATION JANUARY 2018 On December 27, 2017, the Lieutenant Governor signed into law several new requirements aimed at combating the opioid epidemic. On the following
Naloxone and Combating the Opioid Epidemic
Objectives Naloxone and Combating the Opioid Epidemic Jeff Jacobson PharmD Southpointe Pharmacy Discuss the current opioid crisis Define the role of Naloxone in opioid overdose Analyze the barriers to
16 SB 319/AP. Senate Bill 319 By: Senators Jackson of the 2nd, Kirk of the 13th, Unterman of the 45th, Henson of the 41st and Orrock of the 36 th
1 2 3 4 5 6 7 8 9 10 11 12 13 Senate Bill 319 By: Senators Jackson of the 2nd, Kirk of the 13th, Unterman of the 45th, Henson of the 41st and Orrock of the 36 th AS PASSED A BILL TO BE ENTITLED AN ACT
TN Opioid Program. Erica Schlesinger, Pharm.D
TN Opioid Program Erica Schlesinger, Pharm.D Nothing to disclose Disclosures TN Together Governor Haslam s Plan Prevention Establishes limits, decreases supply and dosage of prescription opioids Limits
Medication trends shaping workers compensation. A 2018 update of the prevailing industry influences impacting pharmacy outcomes
Medication trends shaping workers compensation A 2018 update of the prevailing industry influences impacting pharmacy outcomes This page intentionally left blank Trends impacting workers compensation pharmacy
QUESTIONS AND ANSWERS Access to Drugs in Exceptional Circumstances
QUESTIONS AND ANSWERS Access to Drugs in Exceptional Circumstances Published by authority of the Minister of Health Date Adopted 2017/06/09 Effective Date 2017/06/28 Health Products and Food Branch Our
ASSEMBLY, No STATE OF NEW JERSEY. 216th LEGISLATURE INTRODUCED MAY 15, 2014
ASSEMBLY, No. STATE OF NEW JERSEY th LEGISLATURE INTRODUCED MAY, 0 Sponsored by: Assemblyman RONALD S. DANCER District (Burlington, Middlesex, Monmouth and Ocean) Assemblyman HERB CONAWAY, JR. District
NOTICE OF INTENT. Department of Health and Hospitals Board of Dentistry
NOTICE OF INTENT Department of Health and Hospitals Board of Dentistry Fees and Costs; Anesthesia/Analgesia Administration; Continuing Education Requirements (LAC 46:XXXIII.134,.306,.706,.1505,.1607,.1611,.1613,.1709,
Prescription Opioid Overdose in Oregon: A public health perspective
Prescription Opioid Overdose in Oregon: A public health perspective Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist Oregon Public Health Division Oregon Health Authority All-Cause Mortality,
Maine s New Opioid Prescribing Law & the Opioid Crisis: Implications for Providers
Maine s New Opioid Prescribing Law & the Opioid Crisis: Implications for Providers Gordon H. Smith, Esq., Executive Vice President Maine Medical Association May 3, 2016 Facing the Opioid Crisis Today Opioid
Good Samaritan and Naloxone Bill Status Report Carryover 2015 and Special Sessions
Good Samaritan and Naloxone Bill Status Report Carryover 2015 and Special Sessions Research current through January 21, 2015 This project was supported by Grant No. G1399ONDCP03A, awarded by the Office
The Role of the Responsible Pharmacist (RP)
The Role of the Responsible Pharmacist (RP) Pharmaceutical industry perspective Vuyo Mokoena: Senior Manager: Monitoring, Compliance and Professional Conduct (MCPC) Overview Background Legislative provision
Strategies to Prevent Pharmaceutical Waste: Modifying Co-Pay Structures
Modifying Co-Pay Structures Extended producer responsibility (EPR) is a policy approach in which the producer s responsibility for their product extends to the post-consumer management of that product
Role of PMPs in Preventing Substance Abuse National Conference of State Legislatures December 6, 2006 San Antonio, Tx
Role of PMPs in Preventing Substance Abuse National Conference of State Legislatures December 6, 2006 San Antonio, Tx Nick Reuter Division of Pharmacologic Therapy Substance Abuse and Mental Health Services
US H.R.6 of the 115 th Congress of the United States Session
US H.R.6 of the 115 th Congress of the United States 2017-2018 Session This Act may be cited as the Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities
October 20, 2016 Scott K. Proescholdbell, MPH. Opioid Overdose and North Carolina s Public Health and Prevention Strategies
October 20, 2016 Scott K. Proescholdbell, MPH Opioid Overdose and North Carolina s Public Health and Prevention Strategies Deaths per 100,000 population Death Rates* for Three Selected Causes of Injury,
Strategies for Federal Agencies
Confronting Pain Management and the Opioid Epidemic Strategies for Federal Agencies Over the past 25 years, the United States has experienced a dramatic increase in deaths from opioid overdose, opioid
Maryland s Good Samaritan Law
Maryland s Good Samaritan Law Annotated Code of Maryland, Criminal Procedure 1-210 Effective October 1, 2015 1 Maryland Public Opinion Survey (MPOS) Administered online February 20 - March 15, 2015 to
Oklahoma. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Oklahoma Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES
TITLE 16 CHAPTER 10 PART 14 OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES 16.10.14.1 ISSUING AGENCY: New
Pursuant to the authority vested in the Commissioner of Health by section 3369-a of the Public
Medical Use of Marihuana Effective date: 7/12/18 Pursuant to the authority vested in the Commissioner of Health by section 3369-a of the Public Health Law (PHL), Section 1004.2 of Title 10 (Health) of
Maryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy. Date Prescription will Start Denying at the
Maryland Medicaid Pharmacy Program & News ViewsNovember 2013 Maryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy The Antipsychotic Peer Review Program is Expanding!
Crowe Healthcare Webinar Series
Crowe Healthcare Webinar Series Healthcare Providers Ongoing Challenges With Controlled Substances Presented by: Scott Gerard, Healthcare Risk Consulting Partner Eric Jolly, Healthcare Risk Vice President
UTAH S CONTROLLED SUBSTANCE DATABASE PROGRAM (CSDB)
UTAH S CONTROLLED SUBSTANCE DATABASE PROGRAM (CSDB) Harold Rogers Prescription Drug Monitoring Program National Meeting Washington, D.C. August 17 August 19 th, 2016 Marvin H. Sims, C.S. DataBase Administrator
Secretary of the Senate. Chief Clerk of the Assembly. Private Secretary of the Governor
Senate Bill No. 132 Passed the Senate October 14, 2009 Secretary of the Senate Passed the Assembly September 8, 2009 Chief Clerk of the Assembly This bill was received by the Governor this day of, 2009,
1) Louisiana s Opioid Addiction 2) Adopting a Drug Formulary - HB 592 3) What is the ODG Drug Formulary and How is it Used in Workers Comp 4) The
1) Louisiana s Opioid Addiction 2) Adopting a Drug Formulary - HB 592 3) What is the ODG Drug Formulary and How is it Used in Workers Comp 4) The Role of Diagnosis (how it will work with the current treatment
MANAGING THE COSTS OF THE OPIOID EPIDEMIC IN WISCONSIN. State Senator Alberta Darling
MANAGING THE COSTS OF THE OPIOID EPIDEMIC IN WISCONSIN State Senator Alberta Darling A NATIONAL PROBLEM According to the 2014 National Survey on Drug Use and Health: 435,000 Americans have used heroin
Industry s Perspective on the Status of Medical Device Regulations. FUNDISA Workshop 09 & 10 Oct Anele Vutha SAMED Regulatory Committee
Industry s Perspective on the Status of Medical Device Regulations FUNDISA Workshop 09 & 10 Oct 2014 Anele Vutha SAMED Regulatory Committee Today s Topics: 1. Medical Device Definition - Differences 2.
Presentation Objectives
Oregon s PDMP 101 Lisa Millet, MSH, Section Manager Injury and Violence Prevention Section Center for Prevention and Health Promotion Oregon Health Authority Eugene Oregon PDO Summit April 20, 2016 1 Presentation
CDC s Approach to Addressing the Opioid Overdose Epidemic
CDC s Approach to Addressing the Opioid Overdose Epidemic Sarah Bacon National Center for Injury Prevention and Control Division of Unintentional Injury Prevention June 23, 2016 500,000 drug overdose deaths
REGULATORY CHALLENGES IN SOUTH AFRICA
REGULATORY CHALLENGES IN SOUTH AFRICA MEDICINES CONTROL COUNCIL SA Prof Peter Eagles Chairperson Medicines Control Council [Southern African Regional and International Symposium (SARI 2014)] 1 OUTLINE
Virginia. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Virginia Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
Illinois Heroin Crisis Act and Family Physicians. October 14, 2015 Hinsdale Family Medicine Residency Faculty Development Program
Illinois Heroin Crisis Act and Family Physicians October 14, 2015 Hinsdale Family Medicine Residency Faculty Development Program Your speaker s disclosures Executive vice president, Illinois Academy of
Orexo completes 1,080 patient REZOLV study and reports on improved treatment of opioid dependent patients
Press release Orexo completes 1,080 patient REZOLV study and reports on improved treatment of opioid dependent patients Uppsala, Sweden, September 2, 2016 Orexo AB (publ.) announces that the REZOLV retrospective